Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia

Journal of Medical Economics
Lisa J McGarryMilton C Weinstein

Abstract

Ventilator-associated pneumonia (VAP), the most common nosocomial infection in critically ill patients, is associated with significantly longer duration of mechanical ventilation, and increased mortality, hospital days, and health-care costs. A previously published prospective, randomized study established the noninferiority of intravenous (IV) doripenem versus IV imipenem/cilastatin ('imipenem') for VAP. This study compares the economic outcomes of IV therapy with doripenem versus imipenem as first-line treatment for VAP. A decision-analytic model of inpatient care and outcomes for VAP was used to estimate costs associated with VAP treatment. The model calculates total hospital costs, comprising costs of initial and concomitant therapy, and costs associated with mechanical ventilation, intensive care unit stays, and total days in hospital. Total treatment costs for doripenem were $10,630 lower than for imipenem ($71,259 vs. 81,889), driven primarily by differences in costs of mechanical ventilation ($45,224 for doripenem, $57,348 for imipenem). Probabilistic sensitivity analyses found doripenem consistently cost saving versus imipenem in 1,000 simulations. Study limitations include use of a simple model to represent a complex ...Continue Reading

References

Jan 1, 1986·Scandinavian Journal of Infectious Diseases·S R NorrbyE Ottosson
Jan 1, 1985·Medical Decision Making : an International Journal of the Society for Medical Decision Making·P DoubiletB J McNeil
Apr 1, 1996·Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS·A C RodloffW Gaus
Feb 22, 2001·Annals of Internal Medicine·M H Kollef, V J Fraser
Nov 14, 2001·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J HjelmgrenF Andersson
Jul 9, 2004·Current Opinion in Infectious Diseases·Jean CarletAnnie Chalfine
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Jun 9, 2005·Critical Care Medicine·Joseph F DastaCatherine Tak Piech
Oct 11, 2005·Critical Care Medicine·Nasia SafdarSanjay Saint
Jan 24, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Steven J EdwardsJonathan M Plumb

❮ Previous
Next ❯

Citations

Dec 19, 2014·Chemical Biology & Drug Design·Talitha I Verhoef, Stephen Morris
Apr 16, 2019·Critical Care Medicine·M Elizabeth WilcoxChaim M Bell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Alpesh Amin
Journal of Critical Care
John MuscedereVAP Guidelines Committee and the Canadian Critical Care Trials Group
© 2021 Meta ULC. All rights reserved